StockData

Mangoceuticals vs Nexalin Technology

MGRX and NXL side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MGRX and NXL compare

Nexalin Technology is the larger company, worth 9.9 times as much as Mangoceuticals ($34.4M against $3.5M).

Nexalin Technology grew revenue faster over the last twelve months (24.2% versus −38.9% for Mangoceuticals).

Nexalin Technology keeps more of each dollar of sales as profit, with a net margin of −4139% compared with −4791% at Mangoceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMGRXNXL
Size and price
Market cap$3.5M$34.4M
Share price$0.160$1.56
Change, 1 year−86.5%−95.6%
Beta (5Y)−1.162.73
Employees–8
StockData Score
Total score77
Valuation score1 (better)0
Growth score12 (better)
Performance score1 (better)0
Health score45 (better)
Dividend score00
Valuation
P/S11.0× (better)158×
P/B0.3× (better)22.6×
Growth
Revenue growth (TTM)−38.9%24.2% (better)
Profitability
Gross margin54.4%86.2% (better)
Operating margin−3829% (better)−4203%
Net margin−4791%−4139% (better)
Return on equity−95.1% (better)−240%
Return on invested capital−60.7% (better)−2105%
Financial health
Debt / equity0.000.00
Current ratio0.181.25 (better)
Altman Z-score−6.11 (better)−41.21
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.6%0.13%
Held by insiders57.8%22.3%
Insider net buying, 12 months−$21.2K–
Short interest, % of float0.59%0.07%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.